Form 4: Dyne Therapeutics CCO Sells Shares for Tax Obligations

Dyne Therapeutics' Chief Commercial Officer, Johanna Friedl-Naderer, sold shares to cover tax liabilities from RSU vesting, as per pre-arranged Rule 10b5-1 plans.

Summary

• Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc., reported two sales of common stock.
• On September 4, 2025, 894 shares were sold at a weighted average price of $13.27 per share.
• This first sale was to satisfy tax withholding obligations related to restricted stock units (RSUs) granted on September 3, 2024.
• On September 5, 2025, an additional 144 shares were sold at $13.41 per share.
• This second sale also covered tax withholding obligations from RSUs granted on December 4, 2024.
• Both transactions were automatic sales executed under a Rule 10b5-1(c) plan, indicating they were not discretionary trades by the reporting person.
• Following these transactions, Ms. Friedl-Naderer beneficially owns 94,873 shares of Dyne Therapeutics common stock, which includes 74,514 unvested RSUs.

Sentiment

Score: 5

Explanation: The transactions are routine, non-discretionary sales for tax purposes related to RSU vesting, which do not indicate a change in management's confidence or company fundamentals.

Positives

• The sales were non-discretionary and pre-arranged under a Rule 10b5-1(c) plan, indicating they are not a signal of a lack of confidence in the company by the insider.
• The underlying event for the sales is the vesting of restricted stock units, which represents a form of compensation and retention for key management.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Management Comments

• "Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units."
• "The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a 'binding contract' consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitors.

Comparison to Industry Standards

• Insider sales for tax withholding purposes upon the vesting of equity awards are a common and standard practice across various industries for executives receiving equity compensation.
• The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, providing a pre-arranged mechanism for insiders to sell shares without concerns of trading on material non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact, as these are routine, non-discretionary sales for tax purposes and do not signal a change in company fundamentals or management's outlook.

Key Dates

Recommendation

This Form 4 filing details routine, non-discretionary sales by a Chief Commercial Officer to cover tax obligations arising from RSU vesting. Such transactions are common and pre-scheduled under Rule 10b5-1 plans, and therefore do not typically signal a change in the company's fundamental outlook or management's confidence. Investors should not interpret these sales as a negative indicator, and thus, the filing does not warrant a change in investment recommendation.

Keywords

Dyne Therapeutics, DYN, Form 4, Insider Transaction, Stock Sale, RSU, Tax Withholding, Johanna Friedl-Naderer, Chief Commercial Officer, Rule 10b5-1